October Sees Strong Capital Market Rebound with 21 Biopharma Companies Raising Over RMB 2.9 Billion

According to incomplete statistics, biopharmaceutical enterprises financing events in China in October 202421Start; and most of them are earlier rounds of financing, with nine companies raising over 100 million yuan, totaling an estimated amount of2.9 billionRMB above!

Biopharmaceutical Financing Summary for October 2024

Click to view larger image

FromFinancing AmountTo date, the highest amount is 1.942 billion Hong Kong dollars from Akeso Biopharma, followed by 300 million RMB in Series C funding for Limin Pharmaceuticals.

FromFinancing RoundsThis month, the Pre-A round (Pre-A round, Pre-A+ round) had the highest number of financing events, with a total of 5, accounting for 23.8% of all financing events. Next, the A round financing (A round, A+ round) had 4 events, followed by Angel round (Angel round, Angel+ round) and B round (B round, B+ round), each with 3 events. There were 2 IPOs, and the C round and D+ round each had 1 event.

FromGeographical DistributionIn terms of regional activity, the Yangtze River Delta, the Pearl River Delta, and the Beijing-Tianjin-Hebei region are the most active. Specifically, Shanghai has 6 companies, Jiangsu and Beijing each have 4, Guangdong has 3, and Zhejiang has 1, accounting for a high proportion of 85.7%. In contrast, other regions have fewer companies, with Hubei having 2 and Sichuan having 1.

FromSubdivision TrackInvolved fields include regenerative medicine, synthetic biology, innovative drug development, innovative medical devices, and many other areas.